Want to see HK:2633 full AI Analyst Report?
2633 Stock Chart & Stats
HK$1.29
HK$0.01(0.99%)
At close: 4:00 PM EST
HK$1.29
HK$0.01(0.99%)
Day’s Range― - ―
52-Week RangeHK$0.98 - HK$1.69
Previous CloseN/A
Volume1.98M
Average Volume (3M)821.71K
Market Cap
HK$2.03B
Enterprise ValueHK$2.69B
Total Cash (Recent Filing)HK$369.86M
Total Debt (Recent Filing)HK$910.90M
Price to Earnings (P/E)7.1
Beta0.14
Next Earnings
Nov 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield17.82%
Share Statistics
EPS (TTM)0.15
Shares Outstanding2,000,221,000
10 Day Avg. Volume1,775,382
30 Day Avg. Volume821,706
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)1.06
Price to Sales (P/S)1.57
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.15
Revenue Forecast (FY)HK$1.63B
Bulls Say, Bears Say
Bulls Say
Strong MarginsHigh gross (~43%) and net (~19%) margins indicate durable earnings power across the portfolio, supporting reinvestment and cash returns. Sustained margins suggest pricing power or efficient manufacturing, improving long-term cash generation and ability to fund R&D, marketing and dividends.
Improving ROE & Manageable LeverageROE improving to around 13% alongside lower debt-to-equity (~0.39) signals rising capital efficiency and a structurally improved leverage profile. Reduced leverage versus prior years enhances financial flexibility, enabling sustained investment in growth or opportunistic M&A without overburdening cash flow.
Integrated, Diversified Healthcare ModelVertical integration across development, manufacturing, marketing and distribution and exposure to both branded prescription and consumer healthcare diversifies revenue drivers and deepens channel access (hospitals, clinics, pharmacies). This reduces single-channel dependence and supports margin resilience and supply control.
Bears Say
Revenue VolatilityMaterial top-line volatility, highlighted by a sharp 2024 decline and modest recent growth, undermines predictability of long-term revenue. Inconsistent sales trends complicate capacity planning, weaken scale economics for key products, and raise execution risk for new launches and sustained market-share gains.
Weaker Cash Generation TrendA ~25% YoY drop in free cash flow and choppy FCF history reduce reliability of internally generated funding for capex, dividends and strategic initiatives. Limited cash-conversion visibility and missing coverage metrics constrain confidence in sustained cash generation under varying operating conditions.
Reduced Balance-sheet HeadroomDespite improved leverage ratios, rising absolute debt and a step-down in assets/equity since 2023 lower the company's balance-sheet buffer. This reduces resilience to shocks and may limit strategic flexibility for larger investments or acquisitions without additional financing.
Jacobson Pharma Corporation Limited News
2633 FAQ
What was Jacobson Pharma Corporation Limited’s price range in the past 12 months?
Jacobson Pharma Corporation Limited lowest stock price was HK$0.98 and its highest was HK$1.69 in the past 12 months.
What is Jacobson Pharma Corporation Limited’s market cap?
Jacobson Pharma Corporation Limited’s market cap is HK$2.03B.
When is Jacobson Pharma Corporation Limited’s upcoming earnings report date?
Jacobson Pharma Corporation Limited’s upcoming earnings report date is Nov 20, 2026 which is in 121 days.
How were Jacobson Pharma Corporation Limited’s earnings last quarter?
Jacobson Pharma Corporation Limited released its earnings results on Jun 23, 2026. The company reported HK$0.08 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.08.
Is Jacobson Pharma Corporation Limited overvalued?
According to Wall Street analysts Jacobson Pharma Corporation Limited’s price is currently Overvalued.
Does Jacobson Pharma Corporation Limited pay dividends?
Jacobson Pharma Corporation Limited pays a Semiannually dividend of HK$0.048 which represents an annual dividend yield of 17.82%. See more information on Jacobson Pharma Corporation Limited dividends here
What is Jacobson Pharma Corporation Limited’s EPS estimate?
Jacobson Pharma Corporation Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Jacobson Pharma Corporation Limited have?
Jacobson Pharma Corporation Limited has 2,000,221,000 shares outstanding.
What happened to Jacobson Pharma Corporation Limited’s price movement after its last earnings report?
Jacobson Pharma Corporation Limited reported an EPS of HK$0.08 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -2.727%.
Which hedge fund is a major shareholder of Jacobson Pharma Corporation Limited?
Currently, no hedge funds are holding shares in HK:2633
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Jacobson Pharma Corporation Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
80.83%
12-Months-Change
Fundamentals
Return on Equity
17.82%
Trailing 12-Months
Asset Growth
-2.23%
Trailing 12-Months
Company Description
Jacobson Pharma Corporation Limited
Jacobson Pharma Corporation Limited, a subsidiary of Kingshill Development Limited, specializes in the production, promotion, and distribution of generic medications and branded healthcare products. Its market reach extends across Hong Kong, mainland China, Macau, Singapore, and international territories. The company offers a broad selection of generic pharmaceuticals targeting diverse medical conditions, including respiratory, cardiovascular, central nervous system, gastrointestinal, genito-urinary, musculoskeletal, endocrine and metabolic, dermatological, anti-allergic, scar treatment, oral anti-diabetic, and anti-infective categories. Specific examples comprise arsenic trioxide oral solutions, rosuvastatin tablets, and atorvastatin tablets. In addition to generics, the company provides branded medications, health and wellness products, and traditional Chinese remedies. Prominent proprietary Chinese medicines include Po Chai pills, Ho Chai Kung Tji Thung San, Tong Tai Chung Woodlok oil, Flying Eagle Woodlok Oil, Saplingtan, Shiling oil, Contractubex, Doan's Ointment, and Col-gan tablets. Its operations also extend to trading medical provisions, procuring packaging materials, distributing herbal and health-related goods, conducting research and development, and managing property holdings. The company distributes its offerings to a wide range of clients, including hospitals, clinics, authorized pharmacies, independent physicians, retail outlets, and trading companies. Founded in 2016, Jacobson Pharma Corporation Limited is headquartered in Kwun Tong, Hong Kong.
Technical Analysis
China Traditional Chinese Medicine Holdings Co
―
Wai Yuen Tong Medicine Holdings Limited
―
PuraPharm Corp. Ltd.
―
Dawnrays Pharmaceutical Holdings Ltd.
―
Pak Fah Yeow International Limited
―